Navigation Links
Cepheid Receives FDA Clearance for First Rapid On-Demand Molecular Diagnostic Test for MRSA and S. aureus
Date:9/29/2008

s in some markets; reimbursement rates for the products; and underlying market conditions worldwide. Readers should also refer to the section entitled "Risk Factors" in Cepheid's Annual Report on Form 10-K for 2007 and in its most recent quarterly report on Form 10-Q, each filed with the Securities and Exchange Commission.

All forward-looking statements and reasons why results might differ included in this release are made as of the date of this press release, based on information currently available to Cepheid, and Cepheid assumes no obligation to update any such forward-looking statement or reasons why results might differ.

CONTACTS:

For Media Inquiries: For Cepheid Investor Inquiries:

Jared Tipton Jacquie Ross

Cepheid Corporate Cepheid Investor Relations

Communications 408-400-8329

408-400-8377 jacquie.ross@cepheid.com

jared.tipton@cepheid.com


'/>"/>
SOURCE Cepheid
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related biology technology :

1. Cepheid Enters Into Five-Year Agreement With Northrop Grumman for the Purchase of Anthrax Test Cartridges for Use in United States Postal Service Biohazard Detection Systems
2. Cepheid to Present at Thomas Weisel Partners Healthcare Conference
3. Cepheid Enters Agreement To Exclusively License HPV Portfolio Developed by Quantovir AB
4. Cepheid to Present at William Blair Small-Cap Growth Stock Conference
5. Cepheid to Present at the Piper Jaffray 19th Annual Healthcare Conference
6. Cepheid Receives Health Canada Medical Device License for Xpert MRSA(TM) Test and GeneXpert(R) System
7. Cepheid Schedules Teleconference and Webcast for 2007 Fourth Quarter and Full Year Results
8. Cepheid Appoints Senior VP, Chief Financial Officer to Management Team
9. Cepheid and Instrumentation Laboratory Introduce Xpert(TM) HemosIL(R) FII & FV Assay to European Clinical Testing Market
10. Cepheid Reports Fourth Quarter and Full Year 2007 Results
11. Cepheid to Present at Cowen and Companys 28th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2009)LIBREVILLE, Gabon, December 2 , - "Bolstering Biodiversity in Africa: Everyone,s Problem and Heritage" , Coinciding with the International Year of Biodiversity, 2-3 June 2010 the,Gabonese Rep
(Date:12/2/2009)SINGAPORE, Dec. 2 S*BIO Pte Ltd today announced data presentations on its novel oral JAK2 inhibitor, SB1518, at The American Society of Hematology 51st Annual Meeting and Exposition in New Orleans. ,
(Date:12/2/2009)SHANGHAI, Dec. 2 /PRNewswire-Asia/ -- The world is going through,extraordinary times; markets are in turmoil and uncertainty is part of many,businesses and industries. It turns out that the pharma ind
(Date:12/1/2009)INCLINE VILLAGE, Nev., Dec. 1 PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI ) today announced revenue guidance for the fourth quarter ended December 31, 2009 of approximately $57 million, as compared with
Breaking Biology Technology:Libreville International Conference 2-3 June 2010 2S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 2S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 3S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 4S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 5Pharma and Biotech Leaders to Converge in China at Asia Pharma R&D Leaders 2010 Summit 2Pharma and Biotech Leaders to Converge in China at Asia Pharma R&D Leaders 2010 Summit 3PDL BioPharma Provides Fourth Quarter 2009 Revenue Guidance of Approximately $57 Million 2PDL BioPharma Provides Fourth Quarter 2009 Revenue Guidance of Approximately $57 Million 3
...c. (NYSE: CRY ),a biomaterials, medical device an...it is scheduled to participate in the 19th Annual ... Hotel in New York City on Tuesday,November 27, 20...Life, Inc. will deliver,the Company,s presentation...fe,s live presentation may be accessed through its...
...re/ - Cytochroma Inc. announced today,that it has ... CTAP101,Capsules, the Company,s product candidate...hronic kidney disease (CKD). This Phase I/II clin...ed to establish the pharmacokinetic profile and sa...D insufficiency. The product,s,pharmacokinetic pro...
... Third quarter Consolidated Net Income NIS 178 Mil...Quarter 2006 Results Adversely Affected by,Norther...raft Prospectus for the Issue of,Debentures Primar...tures,Were Rated AA Stable by Maalot, a Standard a...ORL) ("Oil Refineries" or the "Company"),announced...
Other Biology Technology:CryoLife to Present at 19th Annual Piper Jaffray Health Care Conference in New York 2Cytochroma initiates Phase I/II clinical trial of CTAP101 Capsules for vitamin D insufficiency in chronic kidney disease 2Oil Refineries Announces Financial Results for Third Quarter and Nine Months 2007 2Oil Refineries Announces Financial Results for Third Quarter and Nine Months 2007 3Oil Refineries Announces Financial Results for Third Quarter and Nine Months 2007 4Oil Refineries Announces Financial Results for Third Quarter and Nine Months 2007 5Oil Refineries Announces Financial Results for Third Quarter and Nine Months 2007 6Oil Refineries Announces Financial Results for Third Quarter and Nine Months 2007 7Oil Refineries Announces Financial Results for Third Quarter and Nine Months 2007 8Oil Refineries Announces Financial Results for Third Quarter and Nine Months 2007 9Oil Refineries Announces Financial Results for Third Quarter and Nine Months 2007 10Oil Refineries Announces Financial Results for Third Quarter and Nine Months 2007 11
(Date:12/3/2009)A coating on windows or solar panels that repels grime and dirt? Expanded battery storage capacities for the next electric car? New Tel Aviv University research, just published in Nature Nanotechnolo
(Date:12/3/2009)ALBUQUERQUE, N.M. Most scientists believe that staph infections are caused by many bacterial cells that signal each other to emit toxins. The signaling process is called quorum sensing because many b
(Date:12/3/2009)Have you ever felt overly upset by a social snubbing? Your genetics, not your friends, may be at fault. , Scientists have long known that opium-like painkillers, called opioids, relieve not only phys
Breaking Biology News(10 mins):A window that washes itself? 2Stopping MRSA before it becomes dangerous is possible, Sandia/UNM researchers find 2Stopping MRSA before it becomes dangerous is possible, Sandia/UNM researchers find 3New research suggests how low doses of radiation can cause heart disease and stroke 59969 1New research suggests how low doses of radiation can cause heart disease and stroke 59969 2Ethiopias climate 27 million years ago had higher rainfall warmer soil 10491 1Ethiopias climate 27 million years ago had higher rainfall warmer soil 10491 2Syphilis survey reveals need for accurate testing for early infection 59960 1
...eath among American men. It is estimated ...se during his lifetime. However, promising new tre...this threatening disease. , One of the most innova...oscopic prostatectomy (removal of the prostate). T...rently one of only a handful of fac...
... vitro fertilization offers couples the best chanc...potentially cause doctors to misdiagnose a small f... say. , Citing concerns about the accuracy of pre...actitioners use to pick the healthiest embryos dur...dure. Their work, described during a recent meetin...
...stem of adult mice appear to play a role in the br... olfactory neurons are especially sensitive to nov...new odors. This level of flexibility suggests tha... adapt to and integrate into other regions of the ...st to injury or disease. The report from research...
Other Biology News:Penn Surgeons Use Completely Robotic Surgery to Successfully Treat Prostate Cancer 2Penn Surgeons Use Completely Robotic Surgery to Successfully Treat Prostate Cancer 3Genetic testing still smart choice, despite uncertainties 2Genetic testing still smart choice, despite uncertainties 3Neurons generated in the adult brain learn to respond to novel stimuli 2
...Microarray is specifically designed for location a...ins by pairing chromatin immunoprecipitation (ChIP...robust hybridization and reliable binding data wit...tives. In addition, Agilent provides flexibility b...
...ore user-friendliness and absolute reliability uni...ion of the Mastercycler ep system. In the past few...ynamically. The same applies to the capabilities r...echnological advances, the challenges of tomorrow ...
...s-based research with S. aureus, Sigma-Genosys has...at contains PCR primers to amplify all open readin...rimer pairs are included to amplify ORFs that are ...eus. The ORFmer set contains primers to amplify al...
...Handler is a high-capacity, plug-and-play bench to...ers, readers and liquid handling systems together ...ibility and intuitive and powerful software. Wheth...nking several modules together to complete a robot...
Biology Products: